/* Accessibility: focus indicators */ a:focus-visible, button:focus-visible, [tabindex]:focus-visible, select:focus-visible, summary:focus-visible { outline: 2px solid #4F46E5 !important; outline-offset: 2px !important; border-radius: 6px; } input:focus-visible, textarea:focus-visible { outline: none !important; border-color: #4F46E5 !important; box-shadow: 0 0 0 3px rgba(79, 70, 229, 0.2) !important; } Skip to main content
JournalistDB
Get Started
KF

Keith Flaherty

Editor-in-Chief, Clinical Cancer Research

Clinical Cancer Research

k***@nature.com Upgrade
Pro only
Natick, Massachusetts, United States
www.nature.com

Beats & Topics

Science Health Artificial Intelligence Media Advising Technology Updates Gaming Ethics Party Ideas Framing Ecotravel Mental Health Media Language Social Media Promotion Wine Interpersonal Care

Industries

Research

Published In

Taylor & Francis Hemonc Today Clinical Cancer Research Nature Cell Press Cancer Discovery Jama Dermatology Nature Reviews Clinical Oncology Healio Annals Of Internal Medicine The Lancet

Recent Article

A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma

Upgrade for article links
54 total articles published · Chief